News | August 09, 2022
Briefs: Zydus Lifesciences and Kimia Biosciences
The inspection concluded with four Form 483 observations. None of the observations were related to data integrity.
The inspection concluded with four Form 483 observations. None of the observations were related to data integrity.
Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.
APIC is a contract development and manufacturing organization (CDMO) that offers a wide range of services such as synthetic route design, pilot manufacturing, investigational medical manufacturing, and commercial production, by making full use of integrated processes that combine organic synthesis technologies and biotechnologies it has cultivated over many years
The 562,000 square feet facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR
The domestic business has registered a single-digit growth on the huge base of last year and this was driven by robust demand across established therapies and brands
With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies
Company will invest approximately ¥16 billion to increase production capacity by approximately 70% to ensure a stable supply
Lupin is the 6th largest company in the Indian Pharmaceutical Market
Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million
Subscribe To Our Newsletter & Stay Updated
